BioNTech cuts 2023 revenue target on reduced prospects for vaccine
FRANKFURT (Reuters) – BioNTech has cut its 2023 revenue target
biontech
BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
By Ludwig Burger FRANKFURT – COVID-19 vaccine maker BioNTech said
BioNTech, Pfizer to start testing universal vaccine for coronaviruses
By Ludwig Burger (Reuters) -Germany’s BioNTech, Pfizer’s partner in COVID-19